Pharmalittle: Swiss authorities probe Novartis over patent used to block rivals; Medicare underserves older Americans with opioid use disorder
Johnson Johnson is buying back up to $5 billion in stock, joining a rush of U.S. companies seeking to avoid a new tax on such repurchases.
Pharmalittle: Swiss authorities probe Novartis over patent used to block rivals; Medicare underserves older Americans with opioid use disorder
Johnson Johnson is buying back up to $5 billion in stock, joining a rush of U.S. companies seeking to avoid a new tax on such repurchases.